Advanced Technology Solutions

Hydrochloride Tablet Tramadol

There is no assurance that the Company will achieve the sales levels that will make its operations profitable or that ANDA filings and approvals will be completed hydrochloride tablet tramadol and obtained as anticipated. The company develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients. Clinical Highlights According to labeling derived from its reference listed drug, Ultram, tramadol has been given in single oral doses of 50mg, 75mg and 100mg to patients with pain following surgical procedures and pain following oral surgery (extraction of impacted molars).
In March, Biovail filed a Complete Response to address routine matters raised in the Approvable Letter received from the FDA in early January. More specifically, these matters involved the resolution of labeling issues only, including, but not limited to, resolution of Hydrochloride tablet tramadol final packaging, content and format for the product's blister card and carton. "The approval of Tramadol ODT is a further establishment of Biovail's patented oral disintegrating tablet technologies, such as FlashDose and Flashtab, and their application to making medicines more acceptable and convenient for patients. " A 2004 study of the American population concluded that nearly 40% of adults have experienced problems with swallowing tablets - and a significant proportion of those fail to comply properly with their prescribed and ongoing dosage. In addition, Ultram(R) ER has received three years of exclusivity for the indication and doses approved.
The statements are inherently uncertain, and actual results could differ materially from the statements made herein. TORONTO -- Biovail Corporation (NYSE:BVF)(TSX:BVF) today announced Hydrochloride tablet tramadol that it has received an Approvable Letter from the United States Food & Drug Administration (FDA) for the New Drug Application (NDA) for its orally disintegrating tablet (ODT) version of the analgesic medication tramadol hydrochloride, intended for the treatment of moderate to moderately severe pain. A study of the American population concluded that Hydrochloride tablet tramadol nearly 40% of adults have experienced problems with swallowing tablets -- and a significant proportion of those fail to comply properly with their prescribed and ongoing dosage. Biovail will manufacture, supply and sell Ultram(R) ODT to hydrochloride tablet tramadol ortho-mcneil for distribution at prices approximately equal to 30% of Ortho-McNeil's net selling price. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. For further details and a discussion of such risks and uncertainties, we encourage you to read Forward-looking Statements found in our Annual Report on Form 10-K for the fiscal year ended March 31, 2001, and in our periodic reports on Forms 10-Q and 8-K (if any). Conditions such as post-procedural pain with swelling, associated with swallowing impairment, that require acute analgesic treatment, will benefit from the immediate orally dissolving tablet form. These mechanisms may contribute independently to the overall profile of hydrochloride tablet tramadol tramadol. Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Ortho-McNeil anticipates an early-2006 launch for Ultram(R) ER and Ultram(R) ODT. At this time, Biovail is in late-stage discussions with hydrochloride tablet tramadol several potential strategic marketing partners. The agreement is Hydrochloride tablet tramadol subject to Hart-Scott-Rodino regulatory clearance in the United States. Food and Drug Administration ("FDA") and Canadian Therapeutic Products Directorate ("TPD") approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, third parties, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission ("SEC") and the Ontario Securities Commission ("OSC"). TORONTO -- Biovail Corporation (NYSE:BVF)(TSX:BVF): -- Agreement Reached with Ortho-McNeil, Inc.